SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)

Area of Science:

• Hematology
• Oncology
• Lymphoma Research

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) subtype.
• The R-CHOP regimen has been the standard first-line treatment for aggressive lymphoma for two decades.
• Despite extensive research, modifications to R-CHOP have not significantly improved outcomes.

Purpose of the Study:

• To review the current standard of care for DLBCL.
• To discuss the evolving landscape of treatments for relapsed or progressive DLBCL.
• To explore the potential impact of novel therapies on future DLBCL management.

Main Methods:

• Literature review of DLBCL treatment strategies.
• Analysis of clinical outcomes for standard and novel therapies.
• Discussion of emerging therapeutic agents and their mechanisms.

Main Results:

• R-CHOP remains the established first-line treatment for DLBCL.
• No R-CHOP modifications have yielded significant clinical outcome improvements.
• Novel therapies, including CAR T-cells and bispecific antibodies, are transforming relapsed DLBCL treatment.

Conclusions:

• While R-CHOP is standard for newly diagnosed DLBCL, its efficacy is limited in relapsed settings.
• Emerging therapies like CAR T-cells, polatuzumab vedotin, tafasitamab, and bispecific antibodies offer new hope for relapsed patients.
• These novel agents are poised to challenge R-CHOP's benchmark status in the future management of DLBCL.